DE69217191T2 - Multipartikel-tablette mit schnellauflösbarkeit - Google Patents
Multipartikel-tablette mit schnellauflösbarkeitInfo
- Publication number
- DE69217191T2 DE69217191T2 DE69217191T DE69217191T DE69217191T2 DE 69217191 T2 DE69217191 T2 DE 69217191T2 DE 69217191 T DE69217191 T DE 69217191T DE 69217191 T DE69217191 T DE 69217191T DE 69217191 T2 DE69217191 T2 DE 69217191T2
- Authority
- DE
- Germany
- Prior art keywords
- agents
- drugs
- tablet
- coated
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000013081 microcrystal Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 27
- 239000004480 active ingredient Substances 0.000 claims description 21
- 239000000654 additive Substances 0.000 claims description 21
- -1 anti-infectives Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003172 expectorant agent Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 4
- 229940035676 analgesics Drugs 0.000 claims description 4
- 229940069428 antacid Drugs 0.000 claims description 4
- 239000003159 antacid agent Substances 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000004004 anti-anginal agent Substances 0.000 claims description 4
- 230000003556 anti-epileptic effect Effects 0.000 claims description 4
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- 230000001062 anti-nausea Effects 0.000 claims description 4
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 239000003793 antidiarrheal agent Substances 0.000 claims description 4
- 229960003965 antiepileptics Drugs 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 229940125715 antihistaminic agent Drugs 0.000 claims description 4
- 229960005475 antiinfective agent Drugs 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940125687 antiparasitic agent Drugs 0.000 claims description 4
- 239000003096 antiparasitic agent Substances 0.000 claims description 4
- 229940124575 antispasmodic agent Drugs 0.000 claims description 4
- 239000003434 antitussive agent Substances 0.000 claims description 4
- 229940124584 antitussives Drugs 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 239000002249 anxiolytic agent Substances 0.000 claims description 4
- 230000000949 anxiolytic effect Effects 0.000 claims description 4
- 229940005530 anxiolytics Drugs 0.000 claims description 4
- 239000002830 appetite depressant Substances 0.000 claims description 4
- 208000037849 arterial hypertension Diseases 0.000 claims description 4
- 230000023555 blood coagulation Effects 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 239000002872 contrast media Substances 0.000 claims description 4
- 239000003218 coronary vasodilator agent Substances 0.000 claims description 4
- 239000000850 decongestant Substances 0.000 claims description 4
- 229940124581 decongestants Drugs 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 229940030606 diuretics Drugs 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 230000003419 expectorant effect Effects 0.000 claims description 4
- 229940066493 expectorants Drugs 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000003326 hypnotic agent Substances 0.000 claims description 4
- 230000000147 hypnotic effect Effects 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 239000008141 laxative Substances 0.000 claims description 4
- 229940125722 laxative agent Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000000510 mucolytic effect Effects 0.000 claims description 4
- 229940066491 mucolytics Drugs 0.000 claims description 4
- 229940035363 muscle relaxants Drugs 0.000 claims description 4
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 239000000419 plant extract Substances 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- 230000033764 rhythmic process Effects 0.000 claims description 4
- 229940125723 sedative agent Drugs 0.000 claims description 4
- 239000000932 sedative agent Substances 0.000 claims description 4
- 230000006016 thyroid dysfunction Effects 0.000 claims description 4
- 229940124549 vasodilator Drugs 0.000 claims description 4
- 239000003071 vasodilator agent Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000004368 Modified starch Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 3
- 239000002269 analeptic agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 3
- 229940127225 asthma medication Drugs 0.000 claims description 3
- 229940039231 contrast media Drugs 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229940116269 uric acid Drugs 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229940125684 antimigraine agent Drugs 0.000 claims description 2
- 239000002282 antimigraine agent Substances 0.000 claims description 2
- 229940124433 antimigraine drug Drugs 0.000 claims description 2
- 238000007907 direct compression Methods 0.000 claims description 2
- 238000002483 medication Methods 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 51
- 210000000214 mouth Anatomy 0.000 description 11
- 239000013078 crystal Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 229960005489 paracetamol Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000007493 shaping process Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920003148 Eudragit® E polymer Polymers 0.000 description 3
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 3
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 3
- 229960001380 cimetidine Drugs 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940124537 antidiarrhoeal agent Drugs 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
1. Multipartikel-Tablette zur oralen Anwendung mit oder ohne
Verwendung von Wasser, wobei die
Zerfallgeschwindigkeit einen Zerfall in weniger als 60
Sekunden bewirkt und die einen Wirkstoff und eine
Mischung von Zusatzstoffen enthält, umfassend eine oder
mehrere den Zerfall bewirkende Substanzen und/oder eine
oder mehrere Treibmittel oder Lösungsmittel,
dadurch gekennzeichnet,
daß der Wirkstoff multipartikulär ist und in Form von
umhüllten Mikrokristallen oder von umhüllten
Mikrokörnern aufgebaut ist.
2. Tablette nach Anspruch 1,
dadurch gekennzeichnet,
daß die Mischung der Zusatzstoffe einen oder mehrere den
Zerfall bewirkende Substanzen vom Typ der
Carboxymethylcellulose oder von unlöslich vernetztem
PVP, ein oder mehrere Treibmittel vom Stärkemehltyp,
modifiziertes Stärkemehl oder mikrokristalline Cellulose
und gegebenenfalls einen Zucker zum direkten Verpressen umfaßt.
3. Tablette nach einem der Ansprüche 1 und 2,
dadurch gekennzeichnet,
daß sie im Mund, in einem Wasserglas oder in flüssigen
oder halbflüssigen Lebensmitteln, wie z.B. Joghurt, insoweit
es sich um pediatrische Verwendung handelt oder
Futtermittel für Tiere, insoweit es sich um eine veterinäre
Anwendung handelt, aufgelöst werden kann.
4. Tablette gemäß einem der Ansprüche 1 bis 3,
dadurch gekennzeichnet,
daß sie mindestens eine der Substanzen der Gruppe
umfassend gastromtestinal Sedativa, Antacida,
Analgetika, Entzündungshemmer,koronare Vasodilatatoren,
periphere und zerebrale Vasodilatatoren, Antiinfektiva,
Antibiotika, Antivirusmittel, Antiparasitenmittel,
Antikrebsmittel, Anxiolytika, Neuroleptika, Stimulantien
des zentralen Nervensystems, Antidepressiva,
Antihistaminika, Mittel gegen Diarrhoe, Laxantien,
Nahrungsergänzungsmittel, Immundepressiva, Mittel gegen
Hypocholesterinemie, Hormone, Enzyme, krampflösende
Mittel, Mittel gegen Angina pectoris, Medikamente zur
Beeinflussung des Herzrythmus, Medikamente, die zur
Behandlung von arterieller Hypertonie verwendet werden,
Antimigränemittel, Medikamente, die die Blutgerinnung
beeinflussen, Antiepileptika, Muskelrelaxantien,
Medikamente, die zur Behandlung von Diabetes verwendet
werden, Medikamente, die zur Behandlung von
Schilddrüsenfehlfunktionen verwendet werden, Diuretika,
Appetitzügler, Asthmamittel, schleimlösende Mittel,
Hustenmittel, schleimregulierende Mittel, Dekongestiva,
Hypnotika, Mittel gegen Übelkeit, blutbildende Mittel,
Harnsäure ausscheidende Mittel, Pflanzenextrakte,
Kontrastmittel in Form von umhüllten Mikrokristallen
beinhaltet.
5. Tablette nach einem der Ansprüche 1 bis 3,
dadurch gekennzeichnet,
daß sie mindestens eine der Substanzen der Gruppe
umfassend gastrointestinal Sedativa, Antacida,
Analgetika, Entzündungshemmer, koronare Vasodilatatoren,
periphere und zerebrale Vasodilatatoren, Antiinfektiva,
Antibiotika, Antivirusmittel, Antiparasitenmittel,
Antikrebsmittel, Anxiolytika, Neuroleptika, Stimulantien
des zentralen Nervensystems, Antidepressiva,
Antihistaminika, Mittel gegen Diarrhoe, Laxantien,
Nahrungsergänzungsmittel, Immundepressiva, Mittel gegen
Hypocholesterinemie, Hormone, Enzyme, krampflösende
Mittel, Mittel gegen Angina pectoris, Medikamente zur
Beeinflussung des Herzrythmus, Medikamente, die zur
Behandlung von arterieller Hypertonie verwendet werden,
Antimigränemittel, Medikamente, die die Blutgerinnung
beeinflussen, Antiepileptika, Muskelrelaxantien,
Medikamente, die zur Behandlung von Diabetes verwendet
werden, Medikamente, die zur Behandlung von
Schilddrüsenfehlfunktionen verwendet werden, Diuretika,
Appetitzügler, Asthmamittel, schleimlösende Mittel,
Hustenmittel, schleimregulierende Mittel, Dekongestiva,
Hypnotika, Mittel gegen Übelkeit, blutbildende Mittel,
Harnsäure ausscheidende Mittel, Pflanzenextrakte,
Kontrastmittel in Form von umhüllten Mikrokörnern
beinhaltet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR919109245A FR2679451B1 (fr) | 1991-07-22 | 1991-07-22 | Comprime multiparticulaire a delitement rapide. |
| PCT/FR1992/000715 WO1993001805A1 (fr) | 1991-07-22 | 1992-07-21 | Comprime multiparticulaire a delitement rapide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69217191D1 DE69217191D1 (de) | 1997-03-13 |
| DE69217191T2 true DE69217191T2 (de) | 1997-08-28 |
Family
ID=9415391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69217191T Expired - Lifetime DE69217191T2 (de) | 1991-07-22 | 1992-07-21 | Multipartikel-tablette mit schnellauflösbarkeit |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0548356B1 (de) |
| JP (1) | JP2820319B2 (de) |
| KR (1) | KR100197465B1 (de) |
| AT (1) | ATE148339T1 (de) |
| CA (1) | CA2092074C (de) |
| DE (1) | DE69217191T2 (de) |
| DK (1) | DK0548356T3 (de) |
| ES (1) | ES2099275T3 (de) |
| FR (1) | FR2679451B1 (de) |
| GR (1) | GR3023281T3 (de) |
| HK (1) | HK1007414A1 (de) |
| WO (1) | WO1993001805A1 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4318577A1 (de) * | 1993-06-04 | 1994-12-08 | Merck Patent Gmbh | Schmiermittelfreie, arzneimittelhaltige Tabletten |
| CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
| DE4333190C2 (de) * | 1993-09-29 | 1996-05-30 | Korsatko Werner Univ Prof Dr E | Zerbeißtablette mit verzögerter Wirkstoff-Freisetzung |
| US5807577A (en) * | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US5807578A (en) * | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| FR2766089B1 (fr) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | Comprime multiparticulaire perfectionne a delitement rapide |
| TW527195B (en) * | 1997-10-09 | 2003-04-11 | Ssp Co Ltd | Fast-soluble solid pharmaceutical combinations |
| FR2771291B1 (fr) * | 1997-11-21 | 2000-02-25 | Ethypharm Lab Prod Ethiques | Spheroides, procede de preparation et compositions pharmaceutiques |
| AU741992B2 (en) * | 1998-03-06 | 2001-12-13 | Adare Pharmaceuticals S.R.L. | Fast disintegrating tablets |
| EP1121103B1 (de) | 1998-05-18 | 2006-12-20 | Takeda Pharmaceutical Company Limited | Im munde zerfallende tablette enthaltend ein benzimidazole |
| FR2781793B1 (fr) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
| FR2785539B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Particules enrobees d'ibuprofene cristallin granule |
| FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
| FR2790387B1 (fr) | 1999-03-01 | 2001-05-18 | Prographarm Laboratoires | Comprime orodispersible presentant une faible friabilite et son procede de preparation |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| DE19931708A1 (de) | 1999-07-08 | 2001-01-18 | Bayer Ag | Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen |
| FR2795962B1 (fr) * | 1999-07-08 | 2003-05-09 | Prographarm Laboratoires | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif |
| DK1405621T3 (da) | 2001-06-20 | 2011-07-18 | Takeda Pharmaceutical | Fremgangsmåde til fremstilling af tablet |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| FR2831820B1 (fr) * | 2001-11-05 | 2004-08-20 | Ethypharm Sa | Comprime orodispersible presentant une grande homogeneite et son procede de preparation |
| GB0204771D0 (en) * | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Fast disintegrating tablets |
| FR2837100B1 (fr) * | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
| MXPA04009968A (es) | 2002-04-09 | 2004-12-13 | Flamel Tech Sa | Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s). |
| US20040005362A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| DE10232020A1 (de) | 2002-07-04 | 2004-02-26 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Neurorezeptoraktive Heteroarencarboxamide |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| FR2861990B1 (fr) | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | Comprimes faiblement doses a reseau de polymeres |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| CA2584957C (en) | 2004-10-21 | 2015-08-25 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| WO2006085497A1 (ja) * | 2005-02-09 | 2006-08-17 | Kissei Pharmaceutical Co., Ltd. | 口腔内崩壊錠 |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US20070082048A1 (en) * | 2005-06-08 | 2007-04-12 | Ronald Warner | Sleep aid formulations |
| MX2009001294A (es) | 2006-08-04 | 2009-05-21 | Ethypharm Sa | Granulo y tableta que se desintegra por vía oral que comprende oxicodona. |
| AU2007280471B2 (en) | 2006-08-04 | 2012-10-18 | Ethypharm | Multilayer orally disintegrating tablet |
| WO2008081891A1 (ja) | 2006-12-28 | 2008-07-10 | Takeda Pharmaceutical Company Limited | 口腔内崩壊性固形製剤 |
| JP5228359B2 (ja) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | 主薬粒子及びその製造方法ならびに口腔内崩壊錠 |
| FR2920311B1 (fr) * | 2007-08-31 | 2010-06-18 | Galenix Innovations | Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation |
| BRPI0817927A2 (pt) | 2007-10-01 | 2015-04-07 | Lesvi Laboratorios Sl | Comprimidos orodispersiveis |
| AR070863A1 (es) | 2008-03-11 | 2010-05-12 | Takeda Pharmaceutical | Preparacion solida de desintegracion oral y metodo para suprimir la ruptura de los granulos finos durante la produccion de un comprimido |
| FR2933299B1 (fr) | 2008-07-04 | 2012-02-03 | Roquette Freres | Mannitol orodispersible |
| SG10201407965XA (en) | 2009-12-02 | 2015-02-27 | Aptalis Pharma Ltd | Fexofenadine microcapsules and compositions containing them |
| FR2962331B1 (fr) | 2010-07-06 | 2020-04-24 | Ethypharm | Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre |
| FR2962550B1 (fr) | 2010-07-06 | 2013-06-14 | Ethypharm Sa | Methode pour lutter contre la soumission chimique, utilisation d'agent colorant pour lutter contre la soumission chimique et composition pharmaceutique permettant la mise en oeuvre de la methode |
| AU2011350396A1 (en) | 2010-12-27 | 2013-07-11 | Takeda Pharmaceutical Company Limited | Orally disintegrating tablet |
| FR2999432B1 (fr) | 2012-12-17 | 2014-12-12 | Ethypharm Sa | Comprimes orodispersibles obtenus par compression moulage |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| PT3449912T (pt) | 2016-06-16 | 2024-05-16 | Towa Pharmaceutical Co Ltd | Comprimido de desintegração por via oral |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1200178B (it) * | 1986-07-23 | 1989-01-05 | Alfa Farmaceutici Spa | Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica |
| DE3887179T2 (de) * | 1987-03-02 | 1994-06-16 | Brocades Pharma Bv | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. |
| CA2019324C (en) * | 1989-07-10 | 1996-08-20 | Robert L. Jerzewski | Fosinopril tablet formulations |
-
1991
- 1991-07-22 FR FR919109245A patent/FR2679451B1/fr not_active Expired - Lifetime
-
1992
- 1992-07-21 DE DE69217191T patent/DE69217191T2/de not_active Expired - Lifetime
- 1992-07-21 AT AT92917134T patent/ATE148339T1/de active
- 1992-07-21 JP JP5502647A patent/JP2820319B2/ja not_active Expired - Lifetime
- 1992-07-21 CA CA002092074A patent/CA2092074C/en not_active Expired - Lifetime
- 1992-07-21 ES ES92917134T patent/ES2099275T3/es not_active Expired - Lifetime
- 1992-07-21 DK DK92917134.6T patent/DK0548356T3/da active
- 1992-07-21 WO PCT/FR1992/000715 patent/WO1993001805A1/fr active IP Right Grant
- 1992-07-21 EP EP92917134A patent/EP0548356B1/de not_active Revoked
-
1993
- 1993-03-22 KR KR1019930700863A patent/KR100197465B1/ko not_active IP Right Cessation
-
1997
- 1997-04-29 GR GR970400945T patent/GR3023281T3/el unknown
-
1998
- 1998-06-25 HK HK98106592A patent/HK1007414A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2679451A1 (fr) | 1993-01-29 |
| CA2092074C (en) | 1998-05-19 |
| CA2092074A1 (en) | 1993-01-23 |
| DK0548356T3 (da) | 1997-08-11 |
| JPH06502194A (ja) | 1994-03-10 |
| HK1007414A1 (en) | 1999-04-09 |
| GR3023281T3 (en) | 1997-07-30 |
| EP0548356A1 (de) | 1993-06-30 |
| AU2417192A (en) | 1993-02-23 |
| KR100197465B1 (en) | 1999-06-15 |
| DE69217191D1 (de) | 1997-03-13 |
| AU666666B2 (en) | 1996-02-22 |
| JP2820319B2 (ja) | 1998-11-05 |
| EP0548356B1 (de) | 1997-01-29 |
| FR2679451B1 (fr) | 1994-09-09 |
| ES2099275T3 (es) | 1997-05-16 |
| WO1993001805A1 (fr) | 1993-02-04 |
| ATE148339T1 (de) | 1997-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69217191T2 (de) | Multipartikel-tablette mit schnellauflösbarkeit | |
| US5464632A (en) | Rapidly disintegratable multiparticular tablet | |
| DE3780222T2 (de) | Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung. | |
| DE69838300T2 (de) | Pharmazeutische suspensionstabletten-zusammenstellungen | |
| DE69821553T2 (de) | Granulatzubereitung enthaltend Simethicon und granuliertes wasserfreies Calciumphosphat | |
| DE3779933T2 (de) | Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung. | |
| DE60036874T2 (de) | Pellet formulierung mit gesteuerter freisetzung | |
| DE60115840T2 (de) | Formulierung mit mehrfach gepulster wirkstofffreisetzung | |
| DE68903442T2 (de) | Feste und poroese einheitsform, enthaltend mikropartikel und/oder nanopartikel und verfahren zu ihrer herstellung. | |
| DE3880762T2 (de) | Orale, acetaminophen enthaltende zusammensetzung mit gesteuerter arzneistoff-freisetzung und verfahren zu ihrer herstellung. | |
| EP0918513B1 (de) | Gut schluckbare orale arzneiform | |
| DE3586600T2 (de) | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. | |
| DE69023183T2 (de) | Rotogranulate und geschmacksabdeckende Überzüge zur Herstellung pharmazeutischer Kautabletten. | |
| JP2916153B2 (ja) | 徐放性製剤 | |
| DE1617374A1 (de) | Verfahren zum Herstellen eines pharmazeutischen Praeparates mit verzoegerter Wirkung | |
| DE2611041C2 (de) | ||
| EP0594570B1 (de) | Colestyramin als lipidsenker enthaltende präparate | |
| DE69009684T2 (de) | Pharmazeutische Zusammensetzungen zur Behandlung gastrointestinaler Störungen. | |
| CH655241A5 (de) | Verfahren zur herstellung therapeutisch wirksamer praeparate mit anhaltendem verlauf der wirkstoff-freisetzung. | |
| DE3538429A1 (de) | Pulver mit gesteuerter freisetzung, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung | |
| DE2323686A1 (de) | Arzneimittelzubereitungsform mit langzeitwirkung und verfahren zu ihrer herstellung | |
| DE3855323T2 (de) | Galenische 2-beta-Mimetik-Formen für die per- und sublinguale Verabreichung | |
| DE3246492A1 (de) | Verfahren zur herstellung therapeutischer praeparate auf der basis von hydroxypropylmethylzellulose mit verlaengertem freisetzungsverlauf | |
| DE69530759T2 (de) | Filmbeschichtete tablette, die paracetamol und domperidone enthält | |
| EP0125634B1 (de) | Verwendung einer sekretolytisch wirkenden Substanz zur Herstellung eines Antischnarchmittels und zur Bekämpfung des Schnarchphänomens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: ETHYPHARM S.A., HOUDAN, FR |
|
| R071 | Expiry of right |
Ref document number: 548356 Country of ref document: EP |